Pacira BioSciences, Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $36.48
- 52-Week Range
- $18.80 – $36.67
- Market Cap
- $1.46B
- P/E (TTM)
- 39.23
- EPS (TTM)
- 0.93
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 2.04
- PEG Ratio
- 0.99
- Return on Equity
- 5.24%
- Return on Assets
- 1.49%
- Gross Margin
- 77.85%
- Operating Margin
- 4.00%
- Profit Margin
- 5.08%
- Current Ratio
- 4.68
- Debt/Equity
- 0.48
- Total Debt
- $340.28M
- Free Cash Flow
- $187.77M
- Revenue Growth
- -1.60%
- Earnings Growth
- 483.30%
- Enterprise Value
- $1.51B
Market Snapshot
About
Pacira BioSciences is a commercial-stage pharmaceutical company focused on non-opioid pain management and regenerative health solutions. The company markets EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic used in surgical settings to manage post-operative pain. Pacira also offers ZILRETTA for osteoarthritis knee pain and iovera° for peripheral nerve treatment. The company is committed to advancing non-opioid alternatives to help reduce opioid use and is headquartered in Parsippany, New Jersey.